These data are of particular relevance, since the negative impact of the CD34+ CD38− CD123+ cell population on the disease-free survival and OS of AML patients has already been documented [50], with this cell population being resistant to chemotherapy [35]. This evidence concerns the gene CD34 and acute myeloid leukemia.